Måndag 17 November | 20:53:18 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-27 18:00 Bokslutskommuniké 2025
2025-11-10 - Kvartalsrapport 2025-Q3
2025-08-27 - Kvartalsrapport 2025-Q2
2025-07-08 - Extra Bolagsstämma 2025
2025-06-05 - X-dag ordinarie utdelning INT 0.00 SEK
2025-06-04 - Årsstämma
2025-05-27 - Kvartalsrapport 2025-Q1
2025-02-28 - Bokslutskommuniké 2024
2024-11-28 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-27 - X-dag ordinarie utdelning INT 0.00 SEK
2024-05-24 - Årsstämma
2024-04-30 - Kvartalsrapport 2024-Q1
2024-02-21 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-09-25 - Extra Bolagsstämma 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-06-07 - Kvartalsrapport 2023-Q1
2023-05-12 - X-dag ordinarie utdelning INT 0.00 SEK
2023-05-11 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2023-01-30 - Extra Bolagsstämma 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-08 - Kvartalsrapport 2022-Q1
2022-05-13 - X-dag ordinarie utdelning INT 0.00 SEK
2022-05-12 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-12-23 - Extra Bolagsstämma 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Intellego Technologies är verksamt inom fotokrom indikatorteknik. Bolaget levererar fotokroma bläck som utformar visuella indikatorer som gör det möjligt att se effekterna av osynligt ultraviolett ljus. Bläcket ändrar färg baserat på exponering för ultraviolett bestrålning eller specifika ämnen. Produkterna används primärt av OEM-tillverkare och används i branschapplikationer globalt. Intellego Technologies grundades 2011 och har sitt huvudkontor i Stockholm.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-11-17 09:00:00

Intellego Technologies AB (“Intellego”) announces that its partner, Shanghai Zhongyou Medical High Tech Co., Ltd (“LiKang”), continues to purchase Intellego’s UV dosimeter products in China following positive feedback from the market. These purchases relate to Intellego’s standardized UV dosimeters which are not classified as medical devices. LiKang has been selling Intellego’s standard dosimeter products during the past year, and more than 1,000 hospitals have started to implement Intellego’s products to quality-assure UV disinfection processes.

The use of UV disinfection is currently subject to a regulatory revision in China, which is expected to make the use of verification products such as Intellego’s dosimeters mandatory. These factors, combined with strong market feedback and a growing customer base, have contributed to LiKang’s increased order activity.

In November 2025, Intellego’s CEO, Claes Lindahl, and Chairman of the Board, Gregory Batcheller, visited LiKang in China to discuss the ongoing collaboration and future expansion. Over the past year, LiKang has carried out extensive market development work and collected substantial feedback from end users, indicating strong customer satisfaction and market potential:

  • 95% of hospitals use colour indicators to verify UV exposure levels, while 3% use radiometers.
  • Approximately 88% of users of Intellego’s dosimeters report being very satisfied with the products.
  • Around 60% consider Intellego’s dosimeters significantly better than competing products, 35% find them somewhat better, and 5% rated Intellego’s products below the competition.
  • Intellego’s dosimeters are now in use at more than 1,000 hospitals in China.
  • A dedicated app system for the disinfection market is under review.
  • Regulatory revision expected in 2026, which would make the use of verification products like Intellego’s mandatory on a continuous basis.
  • For 2026 and onwards, the sales will continue to increase based on the estimation that a hospital will spend between USD 10,000 and 20,000 per month on colour indicators to verify UV disinfection.